Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Circulation. Arrhythmia and Electrophysiology|May 17, 2021
Alcohol Consumption Reduction and Clinical Outcomes of Catheter Ablation for Atrial FibrillationYoshihide Takahashi, Junichi Nitta, Atsushi Kobori, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|April 8, 2024
Incidence of phrenic nerve injury during pulmonary vein isolation using different cryoballoons: data from a large prospective ablation registryShinichi Tachibana, Shinsuke Miyazaki, Junichi Nitta, et al.
Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing|February 10, 2023
Initial multicenter clinical experience with the first-generation endoscopic guided laser balloon in JapanMasahiko Goya, Kenzo Hirao, Kazutaka Aonuma, et al.
Journal of Cardiovascular Electrophysiology|August 27, 2024
Acute procedural safety of the latest radiofrequency ablation catheters in atrial fibrillation ablation: Data from a large prospective ablation registryHirofumi Arai, Shinsuke Miyazaki, Junichi Nitta, et al.
Circulation. Arrhythmia and Electrophysiology|October 26, 2018
Efficacy of Endocardial Ablation of Drug-Resistant Ventricular Fibrillation in Brugada Syndrome: Long-Term OutcomeAhmed Karim Talib, Masahiko Takagi, Akira Shimane, et al.
Frontiers in Cardiovascular Medicine|November 15, 2023
Symptomatic periesophageal vagal nerve injury by different energy sources during atrial fibrillation ablationShinsuke Miyazaki, Atsushi Kobori, Hikari Jo, et al.
European Heart Journal|July 24, 2025
Cryoballoon vs radiofrequency ablation in persistent atrial fibrillation: the CRRF-PeAF trialKoji Miyamoto, Koshiro Kanaoka, Kenji Yodogawa, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 24, 2020
Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and DesignShinya Fujiki, Kenichi Iijima, Masaaki Okabe, et al.
Pageof 9